A detailed history of Metis Global Partners, LLC transactions in Moderna, Inc. stock. As of the latest transaction made, Metis Global Partners, LLC holds 14,834 shares of MRNA stock, worth $546,632. This represents 0.03% of its overall portfolio holdings.

Number of Shares
14,834
Previous 13,020 13.93%
Holding current value
$546,632
Previous $1.55 Million 35.9%
% of portfolio
0.03%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$63.64 - $125.14 $115,442 - $227,003
1,814 Added 13.93%
14,834 $991,000
Q2 2024

Aug 06, 2024

BUY
$101.21 - $166.61 $78,842 - $129,789
779 Added 6.36%
13,020 $1.55 Million
Q1 2024

May 06, 2024

SELL
$85.37 - $115.44 $12,037 - $16,277
-141 Reduced 1.14%
12,241 $1.3 Million
Q4 2023

Feb 06, 2024

SELL
$69.51 - $104.43 $214,229 - $321,853
-3,082 Reduced 19.93%
12,382 $1.23 Million
Q3 2023

Nov 07, 2023

BUY
$96.41 - $126.61 $240,350 - $315,638
2,493 Added 19.22%
15,464 $1.6 Million
Q2 2023

Aug 07, 2023

BUY
$118.5 - $160.53 $355 - $481
3 Added 0.02%
12,971 $1.58 Million
Q1 2023

May 08, 2023

BUY
$135.66 - $197.02 $465,449 - $675,975
3,431 Added 35.98%
12,968 $1.99 Million
Q4 2022

Feb 07, 2023

BUY
$118.38 - $210.04 $424,984 - $754,043
3,590 Added 60.37%
9,537 $1.71 Million
Q3 2022

Nov 08, 2022

BUY
$118.07 - $194.18 $45,575 - $74,953
386 Added 6.94%
5,947 $704,000
Q2 2022

Aug 08, 2022

BUY
$117.13 - $176.59 $3,631 - $5,474
31 Added 0.56%
5,561 $794,000
Q1 2022

May 03, 2022

BUY
$126.46 - $235.05 $309,827 - $575,872
2,450 Added 79.55%
5,530 $953,000
Q4 2021

Feb 11, 2022

BUY
$225.82 - $368.51 $695,525 - $1.14 Million
3,080 New
3,080 $782,000

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $14.4B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Metis Global Partners, LLC Portfolio

Follow Metis Global Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metis Global Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Metis Global Partners, LLC with notifications on news.